δ-Catenin promotes tumorigenesis and metastasis of lung adenocarcinoma

Huang,Fei; Chen,Junying; Wang,Zeng; Lan,Ruilong; Fu,Lengxi; Zhang,Lurong

doi:10.3892/or.2017.6140

δ-Catenin promotes tumorigenesis and metastasis of lung adenocarcinoma

Authors:
- Fei Huang
- Junying Chen
- Zeng Wang
- Ruilong Lan
- Lengxi Fu
- Lurong Zhang
View Affiliations

Affiliations: Central Lab, First Affiliated Hospital of Fujian Medical University, Taijiang, Fuzhou, Fujian 350005, P.R. China
Published online on: December 8, 2017 https://doi.org/10.3892/or.2017.6140
Pages: 809-817

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

δ-Catenin coded by gene CTNND2 has been found to be overexpressed in various types of cancers, including prostate, breast, lung and ovarian cancers. However, the function of δ-catenin in lung carcinoma remains largely unknown. In the present study, we revealed that δ-catenin acts as an oncogene promoting the malignancy of lung adenocarcinoma. When δ-catenin proteins of Lewis lung cells were depleted by knocking out Ctnnd2 via CRISPR/Cas9 technology, the cells lost the tumorigenic and metastatic abilities in vivo. Consistently, overexpression of Ctnnd2 enhances the subcutaneous tumorigenesis and distant metastasis of Lewis lung cells in vivo. However, δ-catenin promotes cell proliferation and cell cycle progression of Lewis lung cells. Mechanistically, δ-catenin enhances G1-S phase transition in cooperation with canonical Wnt signaling in Lewis lung cells. Moreover, δ-catenin promotes oncosphere formation of lung adenocarcinoma cells and is associated with the expression of cancer stem cell markers, which indicates δ-catenin enhances colonization and invasion via cancer stem cell maintenance. Taken together, our data suggest that δ-catenin may serve an important role in the malignancy of lung adenocarcinoma through activating canonical Wnt signaling and cancer stem cell maintenance. Our research indicates that δ-catenin can be a new potential target for the treatment of lung adenocarcinoma.

View Figures

View References

1	Chen Z, Fillmore CM, Hammerman PS, Kim CF and Wong KK: Non-small-cell lung cancers: A heterogeneous set of diseases. Nat Rev Cancer. 14:535–546. 2014. View Article : Google Scholar : PubMed/NCBI
2	Sharma SV, Bell DW, Settleman J and Haber DA: Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 7:169–181. 2007. View Article : Google Scholar : PubMed/NCBI
3	Lu Q, Lanford GW, Hong H and Chen YH: δ-Catenin as a potential cancer biomarker. Pathol Int. 64:243–246. 2014. View Article : Google Scholar : PubMed/NCBI
4	Medina M, Marinescu RC, Overhauser J and Kosik KS: Hemizygosity of delta-catenin (CTNND2) is associated with severe mental retardation in cri-du-chat syndrome. Genomics. 63:157–164. 2000. View Article : Google Scholar : PubMed/NCBI
5	Dai SD, Wang Y, Zhang JY, Zhang D, Zhang PX, Jiang GY, Han Y, Zhang S, Cui QZ and Wang EH: Upregulation of δ-catenin is associated with poor prognosis and enhances transcriptional activity through Kaiso in non-small-cell lung cancer. Cancer Sci. 102:95–103. 2011. View Article : Google Scholar : PubMed/NCBI
6	Wang T, Chen YH, Hong H, Zeng Y, Zhang J, Lu JP, Jeansonne B and Lu Q: Increased nucleotide polymorphic changes in the 5′-untranslated region of δ-catenin (CTNND2) gene in prostate cancer. Oncogene. 28:555–564. 2009. View Article : Google Scholar : PubMed/NCBI
7	Fang Y, Li Z, Wang X and Zhang S: Expression and biological role of δ-catenin in human ovarian cancer. J Cancer Res Clin Oncol. 138:1769–1776. 2012. View Article : Google Scholar : PubMed/NCBI
8	Nopparat J, Zhang J, Lu JP, Chen YH, Zheng D, Neufer PD, Fan JM, Hong H, Boykin C and Lu Q: δ-catenin, a Wnt/β-catenin modulator, reveals inducible mutagenesis promoting cancer cell survival adaptation and metabolic reprogramming. Oncogene. 34:1542–1552. 2015. View Article : Google Scholar : PubMed/NCBI
9	Kim H, He Y, Yang I, Zeng Y, Kim Y, Seo YW, Murnane MJ, Jung C, Lee JH, Min JJ, et al: δ-Catenin promotes E-cadherin processing and activates β-catenin-mediated signaling: Implications on human prostate cancer progression. Biochim Biophys Acta. 1822:509–521. 2012. View Article : Google Scholar : PubMed/NCBI
10	Liu XL, Liu LD, Zhang SG, Dai SD, Li WY and Zhang L: Correlation between expression and significance of δ-catenin, CD31, and VEGF of non-small cell lung cancer. Genet Mol Res. 14:13496–13503. 2015. View Article : Google Scholar : PubMed/NCBI
11	Li XY, Liu SL, Cha N, Zhao YJ, Wang SC, Li WN, Wang EH and Wu GP: Transcription expression and clinical significance of dishevelled-3 mRNA and δ-catenin mRNA in pleural effusions from patients with lung cancer. Clin Dev Immunol. 2012:9049462012. View Article : Google Scholar : PubMed/NCBI
12	Viloria-Petit AM and Wrana JL: The TGFbeta-Par6 polarity pathway: Linking the Par complex to EMT and breast cancer progression. Cell Cycle. 9:623–624. 2010. View Article : Google Scholar : PubMed/NCBI
13	Zuo W and Chen YG: Specific activation of mitogen-activated protein kinase by transforming growth factor-beta receptors in lipid rafts is required for epithelial cell plasticity. Mol Biol Cell. 20:1020–1029. 2009. View Article : Google Scholar : PubMed/NCBI
14	Bertram JS and Janik P: Establishment of a cloned line of Lewis lung carcinoma cells adapted to cell culture. Cancer Lett. 11:63–73. 1980. View Article : Google Scholar : PubMed/NCBI
15	O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH and Folkman J: Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell. 79:315–328. 1994. View Article : Google Scholar : PubMed/NCBI
16	Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE, Norville JE and Church GM: RNA-guided human genome engineering via Cas9. Science. 339:823–826. 2013. View Article : Google Scholar : PubMed/NCBI
17	Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, Hsu PD, Wu X, Jiang W, Marraffini LA, et al: Multiplex genome engineering using CRISPR/Cas systems. Science. 339:819–823. 2013. View Article : Google Scholar : PubMed/NCBI
18	O'Donnell KA, Wentzel EA, Zeller KI, Dang CV and Mendell JT: c-Myc-regulated microRNAs modulate E2F1 expression. Nature. 435:839–843. 2005. View Article : Google Scholar : PubMed/NCBI
19	Dang CV: c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol Cell Biol. 19:1–11. 1999. View Article : Google Scholar : PubMed/NCBI
20	Evan GI and Littlewood TD: The role of c-myc in cell growth. Curr Opin Genet Dev. 3:44–49. 1993. View Article : Google Scholar : PubMed/NCBI
21	Claassen GF and Hann SR: A role for transcriptional repression of p21CIP1 by c-Myc in overcoming transforming growth factor beta-induced cell-cycle arrest. Proc Natl Acad Sci USA. 97:pp. 9498–9503. 2000; View Article : Google Scholar : PubMed/NCBI
22	Chin YE, Kitagawa M, Su WC, You ZH, Iwamoto Y and Fu XY: Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21WAF1/CIP1 mediated by STAT1. Science. 272:719–722. 1996. View Article : Google Scholar : PubMed/NCBI
23	Macleod KF, Sherry N, Hannon G, Beach D, Tokino T, Kinzler K, Vogelstein B and Jacks T: p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev. 9:935–944. 1995. View Article : Google Scholar : PubMed/NCBI
24	Reya T and Clevers H: Wnt signalling in stem cells and cancer. Nature. 434:843–850. 2005. View Article : Google Scholar : PubMed/NCBI
25	Yang Y: Wnt signaling in development and disease. Cell Biosci. 2:142012. View Article : Google Scholar : PubMed/NCBI
26	Salic A, Lee E, Mayer L and Kirschner MW: Control of beta-catenin stability: Reconstitution of the cytoplasmic steps of the wnt pathway in Xenopus egg extracts. Mol Cell. 5:523–532. 2000. View Article : Google Scholar : PubMed/NCBI
27	Cohen P and Goedert M: GSK3 inhibitors: Development and therapeutic potential. Nat Rev Drug Discov. 3:479–487. 2004. View Article : Google Scholar : PubMed/NCBI
28	Visvader JE and Lindeman GJ: Cancer stem cells: Current status and evolving complexities. Cell Stem Cell. 10:717–728. 2012. View Article : Google Scholar : PubMed/NCBI
29	Meacham CE and Morrison SJ: Tumour heterogeneity and cancer cell plasticity. Nature. 501:328–337. 2013. View Article : Google Scholar : PubMed/NCBI
30	Yamada KM and Cukierman E: Modeling tissue morphogenesis and cancer in 3D. Cell. 130:601–610. 2007. View Article : Google Scholar : PubMed/NCBI
31	Bissell MJ and Labarge MA: Context, tissue plasticity, and cancer: Are tumor stem cells also regulated by the microenvironment? Cancer Cell. 7:17–23. 2005. View Article : Google Scholar : PubMed/NCBI
32	Viloria-Petit AM, David L, Jia JY, Erdemir T, Bane AL, Pinnaduwage D, Roncari L, Narimatsu M, Bose R, Moffat J, et al: A role for the TGFbeta-Par6 polarity pathway in breast cancer progression. Proc Natl Acad Sci USA. 106:pp. 14028–14033. 2009; View Article : Google Scholar : PubMed/NCBI
33	Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, Di Virgilio A, Conticello C, Ruco L, Peschle C and De Maria R: Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ. 15:504–514. 2008. View Article : Google Scholar : PubMed/NCBI
34	Giard DJ, Aaronson SA, Todaro GJ, Arnstein P, Kersey JH, Dosik H and Parks WP: In vitro cultivation of human tumors: Establishment of cell lines derived from a series of solid tumors. J Natl Cancer Inst. 51:1417–1423. 1973. View Article : Google Scholar : PubMed/NCBI
35	Győrffy B, Surowiak P, Budczies J and Lánczky A: Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer. PLoS One. 8:e822412013. View Article : Google Scholar : PubMed/NCBI
36	Reynolds A, Leake D, Boese Q, Scaringe S, Marshall WS and Khvorova A: Rational siRNA design for RNA interference. Nat Biotechnol. 22:326–330. 2004. View Article : Google Scholar : PubMed/NCBI
37	Silva JM, Li MZ, Chang K, Ge W, Golding MC, Rickles RJ, Siolas D, Hu G, Paddison PJ, Schlabach MR, et al: Second-generation shRNA libraries covering the mouse and human genomes. Nat Genet. 37:1281–1288. 2005. View Article : Google Scholar : PubMed/NCBI
38	Cho SW, Kim S, Kim JM and Kim JS: Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. Nat Biotechnol. 31:230–232. 2013. View Article : Google Scholar : PubMed/NCBI
39	Hsu PD, Scott DA, Weinstein JA, Ran FA, Konermann S, Agarwala V, Li Y, Fine EJ, Wu X, Shalem O, et al: DNA targeting specificity of RNA-guided Cas9 nucleases. Nat Biotechnol. 31:827–832. 2013. View Article : Google Scholar : PubMed/NCBI
40	Yamada N, Noguchi S, Mori T, Naoe T, Maruo K and Akao Y: Tumor-suppressive microRNA-145 targets catenin δ-1 to regulate Wnt/β-catenin signaling in human colon cancer cells. Cancer Lett. 335:332–342. 2013. View Article : Google Scholar : PubMed/NCBI